Exelixis, Inc. EXEL today announced the presentation of updated
interim data from 144 docetaxel-pretreated patients with metastatic
castration-resistant prostate cancer (mCRPC) and bone metastases treated
with cabozantinib in an ongoing non-randomized expansion (NRE) cohort of
its phase 2 randomized discontinuation trial. Median overall survival
was 10.8 months in a patient population in which 73% of patients had
received two or more prior therapies including docetaxel and
abiraterone, enzalutamide, and/or cabazitaxel. Furthermore, a
retrospective analysis of the interim data shows that early responses in
bone scan, circulating tumor cell (CTC) levels, and pain are associated
with longer median overall survival (OS) as compared to non-responders.
These post hoc findings, particularly the bone scan response results,
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in